The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Mar 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how the use of certain blood-thinning medications, called non-vitamin K antagonist oral anticoagulants (NOACs), affects patients who have a stroke. The goal is to better understand how following the prescribed NOAC treatment impacts the severity of the stroke and the outcomes for patients in both the short term and long term. Researchers will look at the relationship between how well patients stick to their medication and the severity of their stroke, including whether they experience better or worse recovery after the event.

To be eligible for this trial, participants must have atrial fibrillation (a heart condition) and be taking one of the NOAC medications (dabigatran, rivaroxaban, apixaban, or edoxaban). They also need to have experienced a stroke or a related condition while on these medications. Those who join the study will have their NOAC levels measured upon hospital arrival, and their stroke severity and recovery will be monitored over time. This research aims to provide valuable insights into the best ways to manage stroke treatment in patients already using NOACs.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Atrial fibrillation
• • Under dabigatran, rivaroxaban, apixaban or edoxaban therapy.
• • Developing ischemic stroke, transient ischemic attack or intracranial hemorrhage during NOAC therapy.
• Exclusion Criteria:
• • Refuse to provide blood sample for non-vitamin K antagonist oral anticoagulant (NOAC) concentration measurement.
• • Refuse to provide informed consent.